This trial is active, not recruiting.

Condition multiple sclerosis
Phase phase 4
Sponsor Groupe Hospitalier Pitie-Salpetriere
Collaborator Institut National de la Santé Et de la Recherche Médicale, France
Trial identifier NCT00289159, RBM0110


To determine wether multimodal MRI (conventinal T1 and T2 sequences, diffusion, magnetization transfer, spectroscopy) is reproducible; to follow up a cohort of patients with early remmittent MS after treatment with interferon.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model defined population
Time perspective longitudinal

Eligibility Criteria

Male or female participants from 18 years up to 50 years old.

Inclusion Criteria: - MS patients according to Poser's criteria - Remitting evolution (less than two years of evolution) - Aged 18-50 - Immunomodulatory treatment indicated Exclusion Criteria: - Unable to perform MRI

Additional Information

Official title Follow Up by Multimodal MRI of a Cohort of Patients With Early Remitting Multiple Sclerosis (REPROMMS Study).
Principal investigator Ayman Tourbah, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in February 2006.
Information provided to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere.